Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $44.6 million.

  • Sangamo Therapeutics' Non-Current Assets fell 1612.02% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.7 million, marking a year-over-year decrease of 1964.84%. This contributed to the annual value of $49.9 million for FY2024, which is 2964.84% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Non-Current Assets of $44.6 million as of Q3 2025, which was down 1612.02% from $47.7 million recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Non-Current Assets peaked at $325.0 million during Q3 2021, and registered a low of $44.6 million during Q3 2025.
  • For the 5-year period, Sangamo Therapeutics' Non-Current Assets averaged around $167.7 million, with its median value being $165.5 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 3067.93% in 2021, then plummeted by 7292.26% in 2023.
  • Sangamo Therapeutics' Non-Current Assets (Quarter) stood at $323.2 million in 2021, then fell by 18.87% to $262.2 million in 2022, then plummeted by 72.92% to $71.0 million in 2023, then fell by 29.65% to $49.9 million in 2024, then dropped by 10.77% to $44.6 million in 2025.
  • Its Non-Current Assets stands at $44.6 million for Q3 2025, versus $47.7 million for Q2 2025 and $48.6 million for Q1 2025.